SEC Comment Letter for Amryt Pharma plc (CIK 0001783010) — May 18, 2022
Amryt Pharma plc (CIK 0001783010)
Date: May 18, 2022 · CIK: 0001783010 · Accession: 0000000000-22-005494
AI Filing Summary & Sentiment
File numbers found in text: 333-264869
Letter
United States securities and exchange commission logo May 18, 2022 Joseph Wiley Chief Executive Officer Amryt Pharma plc Dept 920a 196 High Road, Wood Green London, United Kingdom, N22 8HH Re:Amryt Pharma plc Registration Statement on Form F-3 Filed May 11, 2022 File No. 333-264869 Dear Dr. Wiley: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Michael Davis at 202-551-4385 or Christine Westbrook at 202-551- 5019 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Boris Dolgonos, Esq.
Show Raw Text
United States securities and exchange commission logo
May 18, 2022
Joseph Wiley
Chief Executive Officer
Amryt Pharma plc
Dept 920a 196 High Road, Wood Green
London, United Kingdom, N22 8HH
Re:Amryt Pharma plc
Registration Statement on Form F-3
Filed May 11, 2022
File No. 333-264869
Dear Dr. Wiley:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Michael Davis at 202-551-4385 or Christine Westbrook at 202-551-
5019 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Boris Dolgonos, Esq.